Compounds with BENZENE fused to AZEPINES.
A selective D1 dopamine receptor agonist used primarily as a research tool.
A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D1-class receptor genes lack INTRONS, and the receptors stimulate ADENYLYL CYCLASES.
Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME.
Drugs that bind to and activate dopamine receptors.
A subfamily of G-PROTEIN-COUPLED RECEPTORS that bind the neurotransmitter DOPAMINE and modulate its effects. D2-class receptor genes contain INTRONS, and the receptors inhibit ADENYLYL CYCLASES.
A dopamine D2/D3 receptor agonist.
Cholecalciferols substituted with two hydroxy groups in any position.
Cell-surface proteins that bind dopamine with high affinity and trigger intracellular changes influencing the behavior of cells.
Hydroxy analogs of vitamin D 3; (CHOLECALCIFEROL); including CALCIFEDIOL; CALCITRIOL; and 24,25-DIHYDROXYVITAMIN D 3.
One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action.
Eighteen carbon fatty acids that comprise the great majority of CASTOR OIL, which is from the seed of RICINUS.
The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption.
A bile salt formed in the liver by conjugation of deoxycholate with taurine, usually as the sodium salt. It is used as a cholagogue and choleretic, also industrially as a fat emulsifier.
The observable response an animal makes to any situation.
(2S-(2 alpha,3 beta(1E,3E,5Z,8Z)))-3-(1,3,5,8-Tetradecatetraenyl)oxiranebutanoic acid. An unstable allylic epoxide, formed from the immediate precursor 5-HPETE via the stereospecific removal of a proton at C-10 and dehydration. Its biological actions are determined primarily by its metabolites, i.e., LEUKOTRIENE B4 and cysteinyl-leukotrienes. Alternatively, leukotriene A4 is converted into LEUKOTRIENE C4 by glutathione-S-transferase or into 5,6-di-HETE by the epoxide-hydrolase. (From Dictionary of Prostaglandins and Related Compounds, 1990)
The relationship between the dose of an administered drug and the response of the organism to the drug.
A strain of albino rat used widely for experimental purposes because of its calmness and ease of handling. It was developed by the Sprague-Dawley Animal Company.
A bile salt formed in the liver by conjugation of deoxycholate with glycine, usually as the sodium salt. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and choleretic.
A bile acid formed by bacterial action from cholate. It is usually conjugated with glycine or taurine. Deoxycholic acid acts as a detergent to solubilize fats for intestinal absorption, is reabsorbed itself, and is used as a choleretic and detergent.
A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.
Enzymes catalyzing the oxidation of arachidonic acid to hydroperoxyarachidonates. These products are then rapidly converted by a peroxidase to hydroxyeicosatetraenoic acids. The positional specificity of the enzyme reaction varies from tissue to tissue. The final lipoxygenase pathway leads to the leukotrienes. EC 1.13.11.- .
Placing of a hydroxyl group on a compound in a position where one did not exist before. (Stedman, 26th ed)
The product of conjugation of cholic acid with taurine. Its sodium salt is the chief ingredient of the bile of carnivorous animals. It acts as a detergent to solubilize fats for absorption and is itself absorbed. It is used as a cholagogue and cholerectic.
Proteins, usually found in the cytoplasm, that specifically bind calcitriol, migrate to the nucleus, and regulate transcription of specific segments of DNA with the participation of D receptor interacting proteins (called DRIP). Vitamin D is converted in the liver and kidney to calcitriol and ultimately acts through these receptors.
The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed)
Chromatography on thin layers of adsorbents rather than in columns. The adsorbent can be alumina, silica gel, silicates, charcoals, or cellulose. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed)
Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed.
Enzymes that catalyze the breakage of a carbon-oxygen bond leading to unsaturated products via the removal of water. EC 4.2.1.
Organic compounds containing both the hydroxyl and carboxyl radicals.
Fractionation of a vaporized sample as a consequence of partition between a mobile gaseous phase and a stationary phase held in a column. Two types are gas-solid chromatography, where the fixed phase is a solid, and gas-liquid, in which the stationary phase is a nonvolatile liquid supported on an inert solid matrix.
A group of 1,2-benzenediols that contain the general formula R-C6H5O2.
An analytical method used in determining the identity of a chemical based on its mass using mass analyzers/mass spectrometers.
The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds.
An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.
The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups.
The 3 alpha,7 alpha,12 alpha-trihydroxy-5 beta-cholanic acid family of bile acids in man, usually conjugated with glycine or taurine. They act as detergents to solubilize fats for intestinal absorption, are reabsorbed by the small intestine, and are used as cholagogues and choleretics.
A microanalytical technique combining mass spectrometry and gas chromatography for the qualitative as well as quantitative determinations of compounds.
An essential branched-chain aliphatic amino acid found in many proteins. It is an isomer of LEUCINE. It is important in hemoglobin synthesis and regulation of blood sugar and energy levels.
An emulsifying agent produced in the LIVER and secreted into the DUODENUM. Its composition includes BILE ACIDS AND SALTS; CHOLESTEROL; and ELECTROLYTES. It aids DIGESTION of fats in the duodenum.
An enzyme of the oxidoreductase class primarily found in PLANTS. It catalyzes reactions between linoleate and other fatty acids and oxygen to form hydroperoxy-fatty acid derivatives.
The chemical alteration of an exogenous substance by or in a biological system. The alteration may inactivate the compound or it may result in the production of an active metabolite of an inactive parent compound. The alterations may be divided into METABOLIC DETOXICATION, PHASE I and METABOLIC DETOXICATION, PHASE II.
Uptake of substances through the lining of the INTESTINES.
The rate dynamics in chemical or physical systems.
Ethers that are linked to a benzene ring structure.
Spectroscopic method of measuring the magnetic moment of elementary particles such as atomic nuclei, protons or electrons. It is employed in clinical applications such as NMR Tomography (MAGNETIC RESONANCE IMAGING).
Widely distributed enzymes that carry out oxidation-reduction reactions in which one atom of the oxygen molecule is incorporated into the organic substrate; the other oxygen atom is reduced and combined with hydrogen ions to form water. They are also known as monooxygenases or hydroxylases. These reactions require two substrates as reductants for each of the two oxygen atoms. There are different classes of monooxygenases depending on the type of hydrogen-providing cosubstrate (COENZYMES) required in the mixed-function oxidation.
A nutritional condition produced by a deficiency of VITAMIN D in the diet, insufficient production of vitamin D in the skin, inadequate absorption of vitamin D from the diet, or abnormal conversion of vitamin D to its bioactive metabolites. It is manifested clinically as RICKETS in children and OSTEOMALACIA in adults. (From Cecil Textbook of Medicine, 19th ed, p1406)
A conditionally essential nutrient, important during mammalian development. It is present in milk but is isolated mostly from ox bile and strongly conjugates bile acids.
The portion of the GASTROINTESTINAL TRACT between the PYLORUS of the STOMACH and the ILEOCECAL VALVE of the LARGE INTESTINE. It is divisible into three portions: the DUODENUM, the JEJUNUM, and the ILEUM.
A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471).
The movement of materials across cell membranes and epithelial layers against an electrochemical gradient, requiring the expenditure of metabolic energy.
A vitamin that includes both CHOLECALCIFEROLS and ERGOCALCIFEROLS, which have the common effect of preventing or curing RICKETS in animals. It can also be viewed as a hormone since it can be formed in SKIN by action of ULTRAVIOLET RAYS upon the precursors, 7-dehydrocholesterol and ERGOSTEROL, and acts on VITAMIN D RECEPTORS to regulate CALCIUM in opposition to PARATHYROID HORMONE.
A superfamily of hundreds of closely related HEMEPROTEINS found throughout the phylogenetic spectrum, from animals, plants, fungi, to bacteria. They include numerous complex monooxygenases (MIXED FUNCTION OXYGENASES). In animals, these P-450 enzymes serve two major functions: (1) biosynthesis of steroids, fatty acids, and bile acids; (2) metabolism of endogenous and a wide variety of exogenous substrates, such as toxins and drugs (BIOTRANSFORMATION). They are classified, according to their sequence similarities rather than functions, into CYP gene families (>40% homology) and subfamilies (>59% homology). For example, enzymes from the CYP1, CYP2, and CYP3 gene families are responsible for most drug metabolism.
Closed vesicles of fragmented endoplasmic reticulum created when liver cells or tissue are disrupted by homogenization. They may be smooth or rough.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential for the normal functioning of nerves and muscles and plays a role in blood coagulation (as factor IV) and in many enzymatic processes.
Organic, monobasic acids derived from hydrocarbons by the equivalent of oxidation of a methyl group to an alcohol, aldehyde, and then acid. Fatty acids are saturated and unsaturated (FATTY ACIDS, UNSATURATED). (Grant & Hackh's Chemical Dictionary, 5th ed)
The restriction of a characteristic behavior, anatomical structure or physical system, such as immune response; metabolic response, or gene or gene variant to the members of one species. It refers to that property which differentiates one species from another but it is also used for phylogenetic levels higher or lower than the species.
The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.
A dual inhibitor of both cyclooxygenase and lipoxygenase pathways. It exerts an anti-inflammatory effect by inhibiting the formation of prostaglandins and leukotrienes. The drug also enhances pulmonary hypoxic vasoconstriction and has a protective effect after myocardial ischemia.
Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.
Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others.
A dihydropyridine derivative, which, in contrast to NIFEDIPINE, functions as a calcium channel agonist. The compound facilitates Ca2+ influx through partially activated voltage-dependent Ca2+ channels, thereby causing vasoconstrictor and positive inotropic effects. It is used primarily as a research tool.
Elements of limited time intervals, contributing to particular results or situations.
Derivatives of phenylacetic acid. Included under this heading are a variety of acid forms, salts, esters, and amides that contain the benzeneacetic acid structure. Note that this class of compounds should not be confused with derivatives of phenyl acetate, which contain the PHENOL ester of ACETIC ACID.
R)-(+)-6-Chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine/AFI253446150 can be provided in Alfa Chemistry. We ... Tel:1-201-478-8534. 1-516-662-5404. Fax: 1-516-927-0118. Address: Suite 212, Waverly Plaza, 755 Waverly Avenue, Holtsville, NY ... Tel:1-201-478-8534. 1-516-662-5404. Fax: 1-516-927-0118. Address: Suite 212, Waverly Plaza, 755 Waverly Avenue, Holtsville, NY ... Home > Product > Heterocyclic Organic Compounds > (R)-(+)-6-Chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine ...
1H-3-benzazepin-7-ol, 8-bromo-2,3,4,5-tetrahydro-3-methyl-5-phenyl- ... DOI: 10.1016/s0024-3205(98)00262-8 Abstract The hallucinogenic effects of lysergic acid diethylamide (LSD) have mainly been ... S Giacomelli 1 , M Palmery, L Romanelli, C Y Cheng, B Silvestrini ... 1 Institute of Pharmacology and Pharmacognosy, University of Rome La Sapienza, Italy. ...
... the present study describes a common change in synaptic regulation of dopamine cells in the ventral tegmental area 1 week … ... DOI: 10.1016/s0896-6273(00)80082-3 Abstract The mesolimbic system is known to play a role in self-administration of opioids and ... 1 The Vollum Institute, Oregon Health Sciences University L474, Portland, 97201, USA. ... the present study describes a common change in synaptic regulation of dopamine cells in the ventral tegmental area 1 week after ...
1H-pyrrole-1-heptanoic acid or (2R-trans)-5-(4-fluoro-phenyl)-2-(1-methylethyl-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H ... 1H-pyrrole-3-carboxamide; and pharmaceutically acceptable salts thereof. ... R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-((1-methylethyl)-3-phenyl-4-[(phenylamino)-carbonyl)]- ... 6-tetrahydro-2H-pyran-2-ones. US4319039. 11 Aug 1980. 9 Mar 1982. Merck & Co., Inc.. Preparation of ammonium salt of ...
8-hydroxy-2-(di-n-propylamino)tetralin). DA. dopamine. DS. discriminative stimulus. NE. norepinephrine. FR. fixed ratio. FRF. ... 1-[2-(diphenylmethoxy)ethyl]-4-(3-phenylpropyl)-piperazine). HDL. high-dose lever. MW. molecular weight. NE. norepinephrine. ... 6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine. VTA. ventral tegmental area. ... In all, the results confirm reports that monoamine reuptake blockers enhance the DS effects of cocaine and indicate that 5-HT ...
0 (Benzazepines); 0 (Isotonic Solutions); 0 (Receptors, Dopamine D1); 0 (Receptors, Vasopressin); 0 (SCH 23390); 0 ( ... 1h after the training phase (consolidation design); retention performance was tested 24h post-training. We found that ... 2,3,4,5-Tetra-Hidro-7,8-Di-Hidroxi-1-Fenil-1H-3-Benzazepina/farmacologia. Dopamina/metabolismo. Neostriado/efeitos dos f rmacos ... 0 (Vasoconstrictor Agents); 50VV3VW0TI (Atenolol); 56-59-7 (Felypressin); YKH834O4BH (Epinephrine). [Em] M s de entrada:. 1507 ...
1H]-3-benzazepine (0.3-3.0 mg/kg) produced either no effect or promoted hyperactivity. Thirty minutes after administration of a ... D2, but Not D1 Dopamine Receptor Agonists Potentiate Cannabinoid-Induced Sedation in Nonhuman Primates , Justin P. Meschler, ... D2, but Not D1 Dopamine Receptor Agonists Potentiate Cannabinoid-Induced Sedation in Nonhuman Primates , Justin P. Meschler, ... D2, but Not D1 Dopamine Receptor Agonists Potentiate Cannabinoid-Induced Sedation in Nonhuman Primates , Justin P. Meschler, ...
Benzazepines: 6-Br-APB • Fenoldopam • SKF-38,393 • SKF-77,434 • SKF-81,297 • SKF-82,958 • SKF-83,959; Ergot-derivatives: ... 6-Br-APB is a synthetic compound that acts as a selective dopamine receptor D1 agonist,[1] with the (R) enantiomer being a ... 2-Fluoroamphetamine • 2-OH-PEA • 2-Phenyl-3-aminobutane • 2-Phenyl-3-methylaminobutane • 2,3-MDA • 3-Fluoroamphetamine • 3- ... 3α-Bis-(4-fluorophenyl)methoxytropane • 3-CPMT • 3-Pseudotropyl-4-fluorobenzoate • Altropane (IACFT) • Brasofensine • CFT (WIN ...
Mentions: Experiment 1 was designed as a pilot study with only 4 gerbils per group for an initial assessment of the role of ... Mentions: Experiment 1 was designed as a pilot study with only 4 gerbils per group for an initial assessment of the role of ... Gerbils were randomly assigned to 1 of 2 groups, A and B, and trained on the FM discrimination task once per day for a total of ... Gerbils were randomly assigned to 1 of 2 groups, A and B, and trained on the FM discrimination task once per day for a total of ...
6-dihydroxy-3-phenyl-1H-2-benzopyran hydrochloride (A-68930), like SKF-38393, produced a dose-dependent, D1-selective increase ... Administration of the selective D1-dopamine receptor agonist 2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine (SKF- ... The full D1-dopamine agonist l,(R,S)1-aminomethyl-3,4-dihydro-5, ...
1. This study compared the effect of a non-peptide angiotensin II receptor antagonist and a series of clonidine analogues on ... Melatonin and 5-methoxytryptophol were approximately equipotent and a dose of 150 micromol/kg brought about a reduction of ... 1. Effects of the alpha2-adrenoceptor agonist dexmedetomidine on vasoconstrictor and heart rate (HR) responses to acute central ... METHODS AND RESULTS: In 11 healthy subjects (7 men, age 27+/-2 years, body mass index 23.1+/-0.7 kg/m2), we compared the ... ...
Benzazepines, Benzodiazepines, Binding Sites, Binding, Competitive, Biogenic Monoamines, Birth Weight, Blinking, Blood Pressure ... Phenyl Ethers, Phosphinic Acids, Phosphites, Photic Stimulation, Phylogeny, Physical Exertion, Physical Stimulation, ... 4 (July, 2005), pp. 447-453 [15971025], [doi] [abs]. *Addy, NA; Pocivavsek, A; Levin, ED, Reversal of clozapine effects on ... 2 (April, 2005), pp. 132-142 [15829222], [doi] [abs]. *Levin, ED; Pizarro, K; Pang, WG; Harrison, J; Ramsdell, JS, Persisting ...
11b-tetrahydro-1H-naph[1,2,3-de]isoquinoline: A potent full dopamine D1 agonist containing a rigid β-phenyldopamine ... 9-Dihydroxy-1,2,3,11b-tetrahydrochromeno[4,3,2,-de]isoquinoline (dinoxyline), a high affinity and potent agonist at all ... benzazepine, 6,7-Dihydroxy-1,2,3,4,8,12b-hexahydroanthr[10,4a,4-cd]azepine, and 10-(Aminomethyl)-9,10-dihydro-1,2- ... D1 dopamine receptors. Huang, X., Lawler, C. P., Lewis, M. M., Nichols, D. E. & Mailman, R. B., Jan 1 2001, In : International ...
... phenyl1H3benzazepine HCl (SK & F 38393) whether injected intracerebrally or peripherally, induced contralateral rotation but ... dihydroxy1,2,3,4‐tetrahydronaphthalene (A‐5, 6 DTN, A‐6, 7 DTN) and N,N dipropyl A‐5, 6DTN induced both responses. In contrast ... tetrahydro7,8dihydroxy1phenyl1H3benzazepine HCl (SK & F 38393) whether injected intracerebrally or peripherally, induced ... dihydroxy1,2,3,4‐tetrahydronaphthalene (A‐5, 6 DTN, A‐6, 7 DTN) and N,N dipropyl A‐5, 6DTN induced both responses. In contrast ...
Fingerprint Dive into the research topics of Stimulation of dopamine D2/D3 but not D1 receptors in the central amygdala decreases cocaine-seeking behavior. Together they form a unique fingerprint. ...
The data of Taylor et al .5 and that of others now highlight the importance of DA in arousal. These findings have direct ... D-1 agonist, SKF 38393, but not a D-2 agonist, produces a cholinergically mediated analeptic effect in rabbits. Pharmacol ... In this issue of ANESTHESIOLOGY, Taylor et al .5 report that the dopamine-1 receptor (D1R) agonist 6-chloro-7,8-dihydroxy-3- ... In the previous study, Horita et al .7 also provide evidence that the dopaminergic effects (driven by D1R but presumably ...
3 H] A-369508 binds with high affinity to the major human dopamine D4 receptor variants D4.2, D4.4 and D4.7 (K d=1.7, 4, and ... In a recent study, racemic 3-(N,N-dimethylamino)butyl-N,N-dimethylcarbamate () was shown to be a potent agonist at neuronal ... 3 H] A-369508 binds to a single, high affinity site on membranes containing the human dopamine D4.4 receptor. When compared to ... 3 H] A-369508 is a useful tool to define the localization and physiological role of dopamine D4 receptors in central nervous ...
Fingerprint Dive into the research topics of D1-D2 interaction in feedback control of midbrain dopamine neurons. Together they form a unique fingerprint. ...
Piribedil (a D3/D2/D1 agonist), a drug under investigation, known to prevent acoustic trauma or ischaemia-induced hearing loss ... D2 agonists and antagonists failed to modulate the release of dopamine, indicating the lack of negative feedback modulation of ... Our results suggest that the release of dopamine was subjected to modulation by a D1 receptor agonist and an antagonist. In ... The effect of both drugs on stimulation-evoked release could be prevented by SKF-83566 (a selective D1 antagonist). However, ...
Ueda, A., Yamamoto, M. & Hirose, N., Apr 1 2011, In : Polar Science. 5, 1, p. 1-10 10 p.. Research output: Contribution to ... Nakanishi, H., Jan 1 1994, In : Physical Review E. 49, 6, p. 5412-5419 8 p.. Research output: Contribution to journal › Article ... Kira, J. I., Dec 1 2010, In : Clinical Neurology. 50, 11, p. 788-793 6 p.. Research output: Contribution to journal › Article ... Inomata, N., Shibata, H., Okuyama, E. & Yamazaki, T., Jan 1 1995, In : Genetics. 141, 1, p. 237-244 8 p.. Research output: ...
F. S., 2018, In : HIV Clinical Trials. 19, 4, p. 158-162 5 p.. Research output: Contribution to journal › Article ... Dopamine inhibits human CD8+ Treg function through D1-like dopaminergic receptors. Nasi, G., Ahmed, T., Rasini, E., Fenoglio, D ... Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients. Dentone, C ... Jan 1 2019, In : Journal of virus eradication. 5, 1, p. 47-49 3 p.. Research output: Contribution to journal › Article ...
Mustard, J. A., Pham, P. M. & Smith, B., Apr 2010, In : Journal of Insect Physiology. 56, 4, p. 422-430 9 p.. Research output: ... Warren, J. P., Santello, M. & Helms Tillery, S., Oct 2010, In : Experimental Brain Research. 206, 4, p. 419-426 8 p.. Research ... Johnston, J. A., Bobich, L. R. & Santello, M., Apr 2010, In : Neuroscience Letters. 474, 2, p. 104-108 5 p.. Research output: ... Brower, J. B., Targovnik, J. H., Caplan, M. & Massia, S., 2010, In : Cytoskeleton. 67, 3, p. 135-141 7 p.. Research output: ...
Y1 - 2013/4/5. N2 - Rationale: It was recently demonstrated that the priming stimulation effect (PSE) in the runway model of ... 1, 05.04.2013, p. 313-321.. Research output: Contribution to journal › Article ... 2013 Apr 5;243(1):313-321. ... Behavioural Brain Research, 243(1), 313-321. ...
Pacheco, L. D., Saad, A. F. & Saade, G., Jul 2020, In: Obstetrics and gynecology. 136, 1, p. 42-45 4 p.. Research output: ... Langsjoen, R. M., Muruato, A. E., Kunkel, S. R., Jaworski, E. & Routh, A., Jul 1 2020, In: mBio. 11, 4, p. 1-20 20 p., e00731- ... Defever, K., Platz, E. A., Lopez, D. S. & Mondul, A. M., Sep 1 2020, In: Cancer Causes and Control. 31, 9, p. 851-860 10 p.. ... Sybenga, A. B., Jupiter, D. C., Speights, V. O. & Rao, A., Jan 1 2020, In: Journal of Foot and Ankle Surgery. 59, 1, p. 75-85 ...
Fingerprint Dive into the research topics of Activation of post-synaptic dopamine D receptors promotes the release of tissue plasminogen activator in the nucleus accumbens via PKA signaling.. Together they form a unique fingerprint. ...
Risnik, V. V., Verin, A. D. & Gusev, N. B., 1985, In: Biochemical Journal. 225, 2, p. 549-552 4 p.. Research output: ... Schaffer, S. W., Tan, B. H. & Mozaffari, M. S., Sep 20 1985, In: The American Journal of Medicine. 79, 3 SUPPL. 2, p. 48-52 5 p ... Olson, J. M., Trunk, J. & Sutherland, J. C., Aug 1 1985, In: Biochemistry. 24, 17, p. 4495-4499 5 p.. Research output: ... Carroll, J. E., Norris, B. J. & Brooke, M. H., Jan 1985, In: Neurology. 35, 1, p. 96-97 2 p.. Research output: Contribution to ...
... and the D-1 agonist SKF 38393 (1.5 mg/kg), either alone or in combination. Treatment with each drug separately did not induce ... and the D-1 agonist SKF 38393 (1.5 mg/kg), either alone or in combination. Treatment with each drug separately did not induce ... and the D-1 agonist SKF 38393 (1.5 mg/kg), either alone or in combination. Treatment with each drug separately did not induce ... and the D-1 agonist SKF 38393 (1.5 mg/kg), either alone or in combination. Treatment with each drug separately did not induce ...
Kawai, F., Horiguchi, M., Suzuki, H. & Miyachi, E. I., 05-07-2002, In: Brain Research. 943, 1, p. 48-55 8 p.. Research output: ... Ohkuma, M., Kawai, F., Horiguchi, M. & Miyachi, E. I., 03-2007, In: Photochemistry and Photobiology. 83, 2, p. 317-322 6 p.. ... Kawai, F., Horiguchi, M., Suzuki, H. & Miyachi, E. I., 2001, In: Neuron. 30, 2, p. 451-458 8 p.. Research output: Contribution ... Kawai, F., 2002, In: Biophysical Journal. 82, 4, p. 2005-2015 11 p.. Research output: Contribution to journal › Article › peer- ...
... phenyl)-1H-pyrazol-3-amine. Ro 20-1724. 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone. ... Ro 4-1284. 2H-Benzo(a)quinolizin-2-ol 2-Ethyl-1,3,4,6,7,11b-hexahydro-3-isobutyl-9,10-dimethoxy-. ... Pregnancy-Specific beta 1-Glycoprotein. Pregnancy-Specific beta 1-Glycoproteins. Tissue Inhibitor of-Metalloproteinase-3. ... trans-1,4-Bis(2-chlorobenzaminomethyl)cyclohexane Dihydrochloride. BW 284 C 51. Benzenaminium, 4,4-(3-oxo-1,5-pentanediyl)bis( ...
  • To facilitate purification and imaging of the D 1 receptor, we attached a polyhistidine tag to the amino terminus and enhanced green fluorescent protein to the carboxyl terminus of the receptor (D 1 -EGFP). (
  • Here we show that dopamine-mediated enhancement of spike firing in NAcb shell medium spiny neurons was prevented by the PKC inhibitor bisindolylmaleimide but not by the phospholipase C inhibitor 1-[6-((17b-3-methoxyestra-1,3,5(10)-trien-17-yl) amino)hexyl]-1H-pyrrole-2,5-dione, suggesting a role for a diacylglycerol-independent atypical PKC (aPKC) isoform. (
  • For experiments with bisindolylmaleimide and 1-[6-((17b-3-methoxyestra-1,3,5(10)-trien-17-yl) amino)hexyl]-1H-pyrrole-2,5-dione ( U73122 ), slices were pre-exposed for 30-60 min to enable adequate penetration, and whole-cell patch was achieved 10-15 min before dopamine application. (
  • Ethyl-3-(2-(((4-Carbamimidoyl Phenyl) Amino) Methyl)-1-Methyl-N-(Pyridin-2-Yl)-1-H-Benzo[D] Imidazole-5-Carboxamido) Propanoate. (
  • As a member of the catecholamine family, 4-(2-aminoethyl)benzene-1,2-diol (dopamine) contains both amino and catechol moieties, each capable of a diversity of potential reactions and interactions. (
  • Tritiation of the dopamine D 4 receptor selective agonist A-369508 ([2-[4-(2-cyanophenyl)-1-piperazinyl]- N -(3-methylphenyl) acetamide) has provided a radioligand for the characterization of dopamine D 4 receptors. (
  • Moreover, the fact that LSD at 10(-8)-10(-6) M antagonized the inhibitory effect of dopamine (10(-7) M) and bromocriptine (10(-11) M) suggests that LSD acts as a partial agonist at D2 receptors on lactotrophs in vitro. (
  • Using knockout mice, we have found that β2-containinc nicotinic receptors appear to be more important for the initiation of nicotine self-administration during the first few weeks, whereas α7 nicotinic receptors appear to be more important for the long-term consumption of nicotine over a period of 5 months. (
  • 5 The results provide evidence that contralateral rotation induced by dopamine receptor agonists is mediated by two different classes of dopamine receptors and that these receptors differ from those mediating the stereotypy response. (
  • In a recent study, racemic 3-( N , N- dimethylamino)butyl- N , N -dimethylcarbamate () was shown to be a potent agonist at neuronal nicotinic acetylcholine receptors with a high selectivity for nicotinic over muscarinic acetylcholine receptors [Mol. (
  • It also binds to the rat dopamine D 4 receptor, ( K d =4.4 nM), implying similar binding affinity across human and rat receptors. (
  • 3 H ] A-369508 is a useful tool to define the localization and physiological role of dopamine D 4 receptors in central nervous system and can facilitate measuring accurate affinities ( K i ) for structure/activity relationship studies designed to identify dopamine D 4 receptor selective agonists. (
  • Furthermore, negative feedback on the stimulation-evoked release of dopamine via D 2 dopamine receptors has been excluded. (
  • In addition, it is concluded that D 2 receptors are not involved in the modulation of dopamine release. (
  • In rats with a unilateral lesion of the dopaminergic nigrostriatal pathway with 6-hydroxydopamine, blockade of N-methyl-D-aspartate receptors by MK-801 strongly potentiated the turning behavior induced by D-1 receptor stimulation. (
  • Molecular genetic studies have also focused on hypothesized associations between various DA related genes and ADHD, with mixed evidence regarding DAT1 and somewhat stronger results with respect to DA receptors DRD4 and DRD5 [ 3 ]. (
  • These receptors are crucial modulators of the motor and cognitive functions mediated by the frontal-striatal circuitry [ 5 , 6 ], functions which are impaired in patients with ADHD. (
  • Receptors, Dopamine D2/drug effects Substances Benzazepines Dopamine Agonists. (
  • In striatal tissue from DARPP-32-depleted mice, basal tyrosine and serine phosphorylation of striatal NMDA receptor subunits NR1, NR2A, and NR2B was normal, and activation of dopamine D1 receptors with the agonist SKF-82958 [(±)-6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4, 5-tetra-hydro-1H-benzazepine] produced redistribution of NMDA receptors from vesicular compartments (P3 and LP2) to synaptosomal membranes (LP1). (
  • Activation of renal dopamine-1 receptors decreases sodium transport. (
  • The dopamine D 1 receptor belongs to the superfamily of heptahelical receptors that modulate the activity of effectors such as adenylate cyclase by activation of specific heterotrimeric GTP-binding proteins (G proteins). (
  • In rat neostriatal neurons, D1 dopamine receptors regulate the activity of cyclic AMP-dependent protein kinase (PKA) and protein phosphatase 1 (PP1). (
  • The findings suggest the presence of both D 1 and D 2 DA receptors in rat anococcygeus muscle and that DA also acts on adrenergic receptors to produce a contractile response of this muscle preparation. (
  • Furthermore, TRPA1 receptors mediate the pruritus induced by activation of PAR-2, but H2S does not interfere with this pathway. (
  • The full D1-dopamine agonist l,(R,S)1-aminomethyl-3,4-dihydro-5,6-dihydroxy-3-phenyl-1H-2-benzopyran hydrochloride (A-68930), like SKF-38393, produced a dose-dependent, D1-selective increase in locomotor activity and striatal c-fos-like immunoreactivity. (
  • In the present study, we report that treatment with 1 microM (+/-)-SKF-38393 hydrochloride, a selective D1 agonist, as well as 100 microM trolox, a lipophilic vitamin E analogue, significantly prevented oxidative-related necrotic cell death following exposure to 10 microM Fe2+ or 1 mM buthionine sulfoximine, an inhibitor of gamma-glutamylcysteine synthetase. (
  • 1 Institute of Pharmacology and Pharmacognosy, University of Rome La Sapienza, Italy. (
  • 2 This work was presented in abstract at the International Union of Pharmacology, Munich, Germany, 1998. (
  • The Journal of Pharmacology and Experimental Therapeutics 275 (3): 1367-74. (
  • Gov't, P.H.S. MeSH Terms 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine/pharmacology Animals Benzazepines/pharmacology Dopamine Agonists/pharmacology Dopamine Antagonists/pharmacology. (
  • European Journal of Pharmacology: Molecular Pharmacology , 269 (3), 375-379. (
  • Nakazawa, K, Akiyama, T & Inoue, K 1994, ' Block by apomorphine of acetylcholine receptor channels expressed in Xenopus oocytes ', European Journal of Pharmacology: Molecular Pharmacology , vol. 269, no. 3, pp. 375-379. (
  • However, pretreatment with the alpha -1 adrenergic antagonist prazosin failed to alter completely the ability of desipramine to enhance the DS effects of the low training dose of cocaine, but did produce dose-related decreases in the cocaine-enhancing effects of the beta adrenergic antagonist propranolol (10 mg/kg i.p. (
  • Fiduxosin is an alpha(1)-adrenoceptor antagonist with higher affinity for alpha(1A)-adrenoceptors and for alpha(1D)-adrenoceptors than for alpha(1B)-adrenoceptors. (
  • When compared to the D 2 -like antagonist [ 3 H ] spiperone, competition binding for agonists like dopamine and apomorphine were 2-10-fold more potent with [ 3 H ] A-369508, while the antagonists clozapine, haloperidol and L-745870 bind with similar affinity to both ligands. (
  • 7 investigated the effects of a D1R agonist (1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol) and a D2R antagonist (raclopride) on duration of phenobarbital anesthesia in rats (administered only 20 min after induction with 40 mg/kg intraperitoneal phenobarbital to reduce pharmacokinetic effects on emergence). (
  • 7 reported that the D2R antagonist raclopride and atropine also reversed the effect of the D1R agonist. (
  • Positive modulation of dopamine release has been shown by a D 1 dopamine receptor agonist, an antagonist and piribedil. (
  • The effect of both drugs on stimulation-evoked release could be prevented by SKF-83566 (a selective D 1 antagonist). (
  • Our results suggest that the release of dopamine was subjected to modulation by a D 1 receptor agonist and an antagonist. (
  • We then assessed the contribution of the basal ganglia motor loops to these impairments, using open field testing and analysis of drug-induced locomotor responses to the psychostimulant cocaine, the benzazepine D 1 receptor agonists SKF83822 and SKF83959, and the NMDA receptor antagonist MK-801. (
  • We tested the hypothesis that the abnormal sodium handling in spontaneously hypertensive rats (Okamoto-Aoki strain) is related to a decreased dopaminergic response by studying the effects of the intrarenal infusion of the dopamine-1 angonist SKF-38393 and the dopamine-1 antagonist SCH-23390 in hypertensive and in normotensive Wistar-Kyoto rats. (
  • Specificity of dopamine-1 effects of SKF-38393 was verified because its natriuretic effect was blocked in a dose-related manner by the dopamine-1 antagonist SCH-2390 (n = 5). (
  • Intrarenal arterial infusion of the dopamine-1 antagonist SCH-23390 alone induced an antinatriuresis, without affecting glomerular filtration rate, in normotensive but not in hypertensive rats. (
  • Addition of the dopamine-2 antagonist YM-09151 to the dopamine-1 antagonist infusion did not enhance the effect of the dopamine-1 antagonist. (
  • D 1 -EGFP was similar to the untagged D 1 receptor in terms of affinity for agonist and antagonist ligands, coupling to G proteins, and stimulation of cyclic AMP accumulation. (
  • The specific dopamine DA1 agonist SKF 82526 caused a dose-dependent inhibition of Na+,K+-ATPase activity, which could be blocked by SCH 23390, a specific DA1 antagonist, and by PKI-(5-24) amide, a specific inhibitor of cAMP-dependent protein kinase. (
  • α 2 antagonists yohimbine (10 -5 M) and idazoxan (10 -5 M) blocked the response to DA in a competitive manner, while α 1 antagonist prazosin (10 -5 M) completely blocked the response to DA. (
  • SCH 23390 (10 -5 M), a D 1 DA antagonist potentiated the response to DA. (
  • An orally active clinical candidate of corticotropin-releasing factor 1 (CRF 1) antagonist 1 showed a significant positive food effect in dog and human after oral administration. (
  • In Experiment 1, the animals received chloropheniramine, a H1 antagonist and then muscimol, a GABA(A) agonist. (
  • The intradermal injection of the PAR-2 peptide agonist SLIGRL-NH2 (8-80nmol) caused a dose-dependent scratching that was unaffected by intraperitoneal pre-treatment with the histamine H1 antagonist pyrilamine (30mg/kg). (
  • Gáborján, A, Lendvai, B & Vízi, E 1999, ' Neurochemical evidence of dopamine release by lateral olivocochlear efferents and its presynaptic modulation in guinea-pig cochlea ', Neuroscience , vol. 90, no. 1, pp. 131-138. (
  • 1999;90(1):131-138. (
  • 1999 Jan 1;21(8):781-784. (
  • We conclude that protein kinase A-dependent phosphorylation of the D 1 receptor on Thr268 regulates a late step in the sorting of the receptor to the perinuclear region of the cell, but that phosphorylation of Thr268 is not required for receptor sequestration or maximal desensitization of cyclic AMP accumulation. (
  • Although the role of protein kinase A (PKA) and dopamine and cyclic adenosine 3′,5′ monophosphate-regulated phosphoprotein 32 kDa in NAcb dopamine receptor throughput has been studied extensively, the contribution of protein kinase C (PKC) to NAcb firing is poorly understood. (
  • Based on these data, we conclude that pruritus secondary to PAR-2 activation can be reduced by H2S, which acts through KATP channel opening and involves NO in a cyclic guanosine monophosphate (cGMP)-independent manner. (
  • with 2-(dimethylamino)ethanol (1:1),mixt. (
  • Product Name 1 4 Chlorobenzhydryl piperazine Synonyms Buclizine Impurity 1 1 4 chlorophenyl phenylmethyl piperazin 1 4 CHLOROBENZYLHYDRYL PIPERAZINE 1 p Chloro phenylbenzyl piperazine Piperazine 1 4 chlorophenyl phenylmethyl NSC 86164 1 4 Chloro a phenylbenzyl piperazine 4 Piperazinobenzyl phenyl chloride CAS 303 26 4. (
  • 3. A compound of claim 1 which is (2R-trans)-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide. (
  • Trans-( )-5-(4-fluorophenyl)-2-(1-methylethyl)-N,4-diphenyl-1-[2-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamides are among compounds of U.S. Pat. (
  • All the monoamine reuptake blockers produced high-dose-appropriate responding in a dose-related manner when combined with a low dose of cocaine, but compounds from other pharmacological classes (benztropine, caffeine, diazepam, or 8-hydroxy-2-(di-n-propylamino)tetralin) did not enhance the DS effects of cocaine. (
  • [0003] Atorvastatin is a competitive inhibitor of the 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase, which is a key enzyme in the biosynthesis of cholesterol in humans. (
  • Second, a better understanding of the neuronal mechanisms by which DA increases the emergence from anesthesia will also help in the management of patients with DA abnormalities as may be the case for patients with Parkinson disease, schizophrenic patients treated with depot neuroleptics (long-acting dopamine-2 receptor [D2R] antagonists) and drug abusers. (
  • D 2 agonists and antagonists failed to modulate the release of dopamine, indicating the lack of negative feedback modulation of dopamine release. (
  • 2-aryloxy-4-alkylaminopyridines: discovery of novel corticotropin-releasing factor 1 antagonists. (
  • The compounds therein broadly include 4- hydroxypyran-2-ones and the corresponding ring-opened acids derived therefrom. (
  • In this study we examined the ability of compounds varying in their in vitro potencies as inhibitors of dopamine (DA), norepinephrine (NE) or serotonin (5-HT) reuptake to enhance the discriminative stimulus (DS) effects of cocaine. (
  • 4. The method of claim 1, wherein the compound is of Formula I or is selected from compounds 1-21 of Table 1. (
  • 7. The method of claim 4, further comprising administering an effective amount of a compound of Formula IV or a compound selected from compounds 44-46 of Table 1. (
  • X-ray structures, solid state periodic DFT modeling and vibrational study of alkylenediammonium hexachlorostannates compounds NH3(CH2)nNH3SnCl6 (n = 3, 4, 5). (
  • In primates, CB 1 cannabinoid receptor agonists produce sedation and psychomotor slowing, in contrast to behavioral stimulation produced by high doses of dopamine receptor agonists. (
  • To investigate whether dopamine agonists attenuate the sedative effects of a cannabinoid agonist in monkeys, we compared the effects of D 1 or D 2 dopamine receptor agonists on spontaneous behavior in three to six cynomolgus monkeys ( Macaca fasicularis ) alone and after administration of a low dose of the CB 1 agonist levonantradol. (
  • Thirty minutes after administration of a threshold dose of levonantradol (0.03 mg/kg), D 2 -type agonists, but not the D 1 agonist, precipitated marked sedation, ptosis, and decreased general activity and locomotor activity. (
  • Cannabinoid agonists and D 2 dopamine agonists should be combined with caution. (
  • [ 2 ] (R)-6-Br-APB and similar D 1 -selective full agonists like SKF-81297 and SKF-82958 produce characteristic anorectic effects, stereotyped behaviour and self-administration in animals, with a similar but not identical profile to that of dopaminergic stimulant drugs such as amphetamine. (
  • MARRIOTT, A.S. 1982-09-01 00:00:00 1 The relative potencies of dopamine receptor agonists in causing stereotypy in rats when injected into the olfactory tubercles, and contralateral rotation when injected unilaterally into the caudate nucleus of rats with lesions of the nigro‐striatal dopamine pathway, were determined. (
  • Specifically, dysregulation of dopamine (DA) has been hypothesized in ADHD based on the potent efficacy of indirect dopaminergic agonists, such as methylphenidate, supported by in vivo evidence that methylphenidate effects are related to striatal occupancy of the dopamine transporter (DAT), by increasing extracellular dopamine levels in the striatum [ 2 ]. (
  • Many of feeding-related receptor agonists act not only in the hypothalamus but also in extrahypothalamic, telencephalic, mesencephalic and metencephalic areas thereby contributing to the regulation of behavior, as has been confirmed by numerous studies [5,7-17]. (
  • Here we present the synthesis and pharmacological characterization of a series of analogs of , where the methyl group at C-3 has been replaced by different alkyl substituents. (
  • Birth Defects Research Part A: Clinical and Molecular Teratology, vol. 73 no. 7 (July, 2005), pp. 481-484 [ 15959889 ], [ doi ]. (
  • 4 The molecular mechanisms for these effects are still incompletely understood. (
  • These findings suggest that D1R-induced suppression of the cell cycle progression in EGF-supported fetal cortical precursor cells represents a net effect of competing cell cycle promoting and inhibiting molecular changes, which involve cyclin D, P27 and Raf-1. (
  • Name Ethyltriphenylphosphonium bromide CasNo 1530 32 1 Molecular Formula C20H20BrP Appearance White crystal powder Application suzuki reaction PTC catalyst DeliveryTime c a 10 days depending on QTY PackAge 25KG carton and others Port Qingdao Shanghai Tianjin Ningbo ProductionCapacity 30 Metric Ton Month Purity min 99. (
  • Product Name 29H 31H phthalocyaninato 2 N29 N30 N31 N32 copper Synonyms Copper 29H 31H phthalocyaninato 2 N29 N30 N31 N32 57373711 57196409 SP 4 1 Copper phthalocyaninato 2 phthalocyanine blueB15 0 SP 4 1 29H 31H phthalocyaninato 2 N29 N30 N31 N32 Copper 29H 31H phthalocyaninato 2 N29 N30 N31 N32 SP 4 1 copper alpha. (
  • Product Name 2b 3a 5a 16b 17b 2 4 Morpholinyl 16 1 pyrrolidinyl androstane 3 17 diol Synonyms Androstane 3 17 diol 2 4 morpholinyl 16 1 pyrrolidinyl 2b 3a 5a 16b 17b 2 4 morpholinyl 16 1 pyrrolidinyl androstane 3 17 diol 9CI The intermediate of LK 7 2 morpholin 4 yl 16 pyrrolidin 1 yl 5 androstane 3 17 diol Rocuronium. (
  • Product Name 3aR 5R 6S 7R 7aR 6 7 dihydroxy 5 hydroxyMethyl 2 Methyl 5 6 7 7a tetrahydro 3aH pyrano 3 2 d thiazole Synonyms NAG thiazoline 57373703 57196397 3aR 5R 6S 7R 7aR 6 7 dihydroxy 5 hydroxymethyl 2 methyl 5 6 7 7a tetrahydro 3aHpyrano 3 2 d thiazole 3aR 5R 6S 7R 7aR 6 7 dihydroxy 5 hydroxyMethyl 2 Methyl 5 6 7. (
  • Founded in January 2017, the group MISSP consists of 12 permanent researchers from the CNRS, the ENSCL and the University Lille 1. (
  • Although G αq and G α11 are expressed together in almost every cell type, the relative levels of expression vary across brain regions with G αq expression being 2-5 times higher than G α11 in most areas ( Milligan, 1993 ). (
  • The dopamine D1 receptor agonist (+/-)-6-chloro-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide (SKF 82958) produced effects comparable to cocaine. (
  • doi: 10.1016/s0024-3205(98)00262-8. (
  • doi: 10.1016/s0896-6273(00)80082-3. (
  • JPET articles become freely available 12 months after publication, and remain freely available for 5 years. (
  • This graph shows the total number of publications written about "Benzazepines" by people in Harvard Catalyst Profiles by year, and whether "Benzazepines" was a major or minor topic of these publication. (
  • n = 4) or pergolide (0.01-1.0 mg/kg) or a D 1 dopamine agonist 6-chloro-7,8-dihydroxy-1-phenyl-2,3,4,5-tetrahydro-3-allyl-[1H]-3-benzazepine (0.3-3.0 mg/kg) produced either no effect or promoted hyperactivity. (
  • 5 report that the dopamine-1 receptor (D1R) agonist 6-chloro-7,8-dihydroxy-3-allyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine hydrobromide but not the D2R agonist quinpirole reduces the time to emergence from isoflurane anesthesia in rats by 85% compared with placebo. (
  • The aim of the present study was to investigate the effects of 6-chloro-7,8-dihydroxy-1-phenyl-2,3, 4,5-tetrahydro-1H-3-benzazepine (SKF81297), a selective agonist of dopaminergic D1 receptor, on the secretion of catecholamines (CA) evoked by cholinergic stimulation and membrane-depolarization in the isolated perfused rat adrenal gland, and also to elucidate the mechanism involved. (
  • Here, we report that the D1/D5 dopamine receptor agonist SKF-38393 substantially improved gerbils' FM discrimination learning when administered systemically or locally into the auditory cortex shortly before, shortly after, or 1 day before conditioning. (
  • To determine the functional consequences of such positive interaction we measured the local rates of cerebral glucose utilization (lCMR(glc)) in lesioned rats treated with MK-801 (0.1 mg/kg) and the D-1 agonist SKF 38393 (1.5 mg/kg), either alone or in combination. (
  • Components of behavioural arousal induced by the dopamine D-1 agonist SKF 38393, the dopamine D-2 agonist RU 24213 and the mixed D-1/D-2 agonist apomorphine were assessed using a behavioural check-list method. (
  • Intrarenal arterial infusion of the dopamine-1 agonist SKF-38393 did not affect glomerular filtration rate but resulted in a dose-related natriuresis and diuresis in normotensive but not in hypertensive rats. (